📣 VC round data is live. Check it out!
- Public Comps
- Alexandria Real Estate
Alexandria Real Estate Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alexandria Real Estate and similar public comparables like Vicinity Centres, Lineage, CubeSmart, CTP and more.
Alexandria Real Estate Overview
About Alexandria Real Estate
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
Founded
1994
HQ

Employees
514
Website
Sectors
Financials (LTM)
EV
$21B
Valuation Multiples
Start free trialAlexandria Real Estate Financials
Alexandria Real Estate reported last 12-month revenue of $3B and EBITDA of $2B.
In the same LTM period, Alexandria Real Estate generated $2B in gross profit, $2B in EBITDA, and had net loss of ($816M).
Revenue (LTM)
Alexandria Real Estate P&L
In the most recent fiscal year, Alexandria Real Estate reported revenue of $3B and EBITDA of $2B.
Alexandria Real Estate is unprofitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 70%, and net margin of (49%).
Financial data powered by Morningstar, Inc.
Alexandria Real Estate Stock Performance
Alexandria Real Estate has current market cap of $8B, and enterprise value of $21B.
Market Cap Evolution
Alexandria Real Estate's stock price is $46.17.
Alexandria Real Estate share price increased by 14.0% in the last 30 days, and decreased by 34.2% in the last year.
Alexandria Real Estate has an EPS (earnings per share) of $-8.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21B | $8B | -2.3% | 14.0% | -14.6% | -34.2% | $-8.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlexandria Real Estate Valuation Multiples
Alexandria Real Estate trades at 7.2x EV/Revenue multiple, and 10.9x EV/EBITDA.
EV / Revenue (LTM)
Alexandria Real Estate Financial Valuation Multiples
As of May 15, 2026, Alexandria Real Estate has market cap of $8B and EV of $21B.
Alexandria Real Estate has a P/E ratio of (9.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alexandria Real Estate Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Alexandria Real Estate Margins & Growth Rates
Alexandria Real Estate decreased revenue by 9% and EBITDA by 24% in the last fiscal year.
In the most recent fiscal year, Alexandria Real Estate reported gross margin of 69%, EBITDA margin of 70%, and net margin of (49%).
Alexandria Real Estate Margins
Alexandria Real Estate Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Alexandria Real Estate Operational KPIs
Alexandria Real Estate's revenue per employee in the last FY averaged $5.7M, while opex per employee averaged $2.9M for the same period.
Alexandria Real Estate's Rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alexandria Real Estate's Rule of X is 35% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Alexandria Real Estate Competitors
Alexandria Real Estate competitors include Vicinity Centres, Lineage, CubeSmart, CTP, Balder, Boston Properties, GPT Group, Camden Property Trust, Knowledge Realty Trust and Mirvac Group.
Most Alexandria Real Estate public comparables operate across Buildings & Property.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 12.3x | 17.1x | 13.5x | 18.5x | |||
| 3.2x | 3.2x | 13.1x | 13.2x | |||
| 11.1x | 11.1x | 17.6x | 17.5x | |||
| 17.0x | 20.5x | 9.9x | 22.6x | |||
| 14.5x | 14.5x | 14.3x | 21.0x | |||
| 7.3x | 7.3x | 13.0x | 13.1x | |||
| 14.0x | 15.3x | 11.6x | 16.2x | |||
| 9.2x | 9.3x | 12.6x | 16.4x | |||
This data is available for Pro users. Sign up to see all Alexandria Real Estate competitors and their valuation data. Start Free Trial | ||||||
Alexandria Real Estate Investment Activity
Alexandria Real Estate has invested in 56 companies to date.
Latest investment by Alexandria Real Estate was on January 7th 2026. Alexandria Real Estate invested in Mediar Therapeutics in their $76M Series B round (EV/Revenue multiple of ).
Latest Investments by Alexandria Real Estate
| Description | Mediar Therapeutics is a Cambridge, Massachusetts-headquartered biotechnology firm focused on pre-clinical therapeutics targeting fibrosis in organs such as lungs, liver, and kidneys. Its pipeline includes small-molecule inhibitors of key fibrotic mediators like TNIK and MRCK, aiming to halt disease progression in idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis. Founded in 2019, the company collaborates with academic institutions and leverages proprietary screening platforms to advance candidates toward clinical trials. Mediar Therapeutics operates from facilities in the Kendall Square biotech hub, positioning it among emerging players in fibrotic disease innovation. | Congruence Therapeutics is a Seattle-based biotechnology firm that integrates computational and experimental methods to develop small-molecule drugs targeting protein misfolding diseases. | Galatea Bio is a United States-based biotechnology company that analyzes genetic diversity from underrepresented populations using its clinical network and biobank in Mexico. The firm develops diagnostic tests and therapies through advanced algorithms, targeting rare diseases and precision medicine applications. | Radiant Biotherapeutics is a biotechnology company developing multi-valent, multi-specific antibody therapeutics. Its proprietary platform enables precise targeting of complex diseases like cancer and autoimmune disorders. Based in Pasadena, California, the firm advances candidates into clinical trials for oncology indications. Radiant Biotherapeutics licenses technology from Caltech for molecular engineering. | |
| HQ Country | |||||
| HQ City | — | Montreal | Miami, FL | Toronto | |
| Deal Date | 7 Jan 2026 | 4 Sep 2025 | 27 Mar 2025 | 25 Apr 2023 | |
| Round | Series B | Undisclosed stage | Series A | Seed | |
| Raised | $76M | $32M | $8M | $8M | |
| Investors | Alexandria Real Estate; Amplitude Venture Capital; Asahi Kasei Pharma; Intermediate Capital Group; Longwood Fund | Alexandria Real Estate; Amplitude Venture Capital; BDC Capital; Driehaus Capital Management; Fonds de solidarité FTQ; Investissement Quebec; Lumira Ventures; OrbiMed; SilverArc Capital | Alexandria Real Estate; Alix Ventures; AME Cloud Ventures; CEI Ventures; Chan Zuckerberg Biohub; Citta Capital; Digitalis Ventures; F-Prime; Founder Collective; HBM Genomics; Helios Fairfax Partners; Stanford University | Alexandria Real Estate; Amplitude Venture Capital; FACIT; SickKids Foundation; Toronto Innovation Acceleration Partners | |
| Valuation | undisclosed | undisclosed | undisclosed | $65M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Alexandria Real Estate investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alexandria Real Estate
| When was Alexandria Real Estate founded? | Alexandria Real Estate was founded in 1994. |
| Where is Alexandria Real Estate headquartered? | Alexandria Real Estate is headquartered in United States. |
| How many employees does Alexandria Real Estate have? | As of today, Alexandria Real Estate has over 514 employees. |
| Who is the CEO of Alexandria Real Estate? | Alexandria Real Estate's CEO is Peter M. Moglia. |
| Is Alexandria Real Estate publicly listed? | Yes, Alexandria Real Estate is a public company listed on NYSE. |
| What is the stock symbol of Alexandria Real Estate? | Alexandria Real Estate trades under ARE ticker. |
| When did Alexandria Real Estate go public? | Alexandria Real Estate went public in 1997. |
| Who are competitors of Alexandria Real Estate? | Alexandria Real Estate main competitors include Vicinity Centres, Lineage, CubeSmart, CTP, Balder, Boston Properties, GPT Group, Camden Property Trust, Knowledge Realty Trust, Mirvac Group. |
| What is the current market cap of Alexandria Real Estate? | Alexandria Real Estate's current market cap is $8B. |
| What is the current revenue of Alexandria Real Estate? | Alexandria Real Estate's last 12 months revenue is $3B. |
| What is the current revenue growth of Alexandria Real Estate? | Alexandria Real Estate revenue growth (NTM/LTM) is (6%). |
| What is the current EV/Revenue multiple of Alexandria Real Estate? | Current revenue multiple of Alexandria Real Estate is 7.2x. |
| Is Alexandria Real Estate profitable? | Yes, Alexandria Real Estate is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alexandria Real Estate? | Alexandria Real Estate's last 12 months EBITDA is $2B. |
| What is Alexandria Real Estate's EBITDA margin? | Alexandria Real Estate's last 12 months EBITDA margin is 66%. |
| What is the current EV/EBITDA multiple of Alexandria Real Estate? | Current EBITDA multiple of Alexandria Real Estate is 10.9x. |
| What is the current FCF of Alexandria Real Estate? | Alexandria Real Estate's last 12 months FCF is $785M. |
| What is Alexandria Real Estate's FCF margin? | Alexandria Real Estate's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of Alexandria Real Estate? | Current FCF multiple of Alexandria Real Estate is 26.1x. |
| How many companies Alexandria Real Estate has acquired to date? | Alexandria Real Estate hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Alexandria Real Estate has invested to date? | As of May 2026, Alexandria Real Estate has invested in 56 companies. |
| What was the last Alexandria Real Estate investment? | On 7th January 2026 Alexandria Real Estate invested in Mediar Therapeutics, participating in a $76M Series B round, alongside Amplitude Venture Capital, Asahi Kasei Pharma, Intermediate Capital Group, and Longwood Fund. |
| In what companies Alexandria Real Estate invested in? | Alexandria Real Estate invested in Relay Therapeutics, Halio, C2i Genomics, Vividion Therapeutics, KSQ Therapeutics, Mediar Therapeutics, NextCure, Stablix, Codiak Biosciences, Kojin Therapeutics, Syros Pharmaceuticals, Kineta (Reverse Merger With Yumanity Therapeutics), Triplet Therapeutics, Petra Pharma, IDEAYA Biosciences, Kallyope, Synthego, Flex Pharma, Inhibrx Biosciences, BlackThorn Therapeutics, and 36 other companies. |
See public comps similar to Alexandria Real Estate
Lists including Alexandria Real Estate
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

